Overview

A Phase 2a Proof of Concept Open-Label, Randomized, Controlled Study to Evaluate the Safety and Efficacy of MDI-1228-mesylate Gel Compared With Standard of Care Alone in Patients With Diabetic Foot Ulcers

Status:
RECRUITING

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

The study will evaluate the treatment effect of MDI-1228-mesylate Gel compared with standard of care alone for the complete healing rate at the end of 12 weeks in participants with diabetic foot ulcers (targeted ulcer). In addition, the proportion of subjects whose target ulcer area is reduced by 50% after 12 weeks of treatment.

Phase:

PHASE2

Details

Lead Sponsor:

Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd.

Treatments:

Standard of Care